The Expression And Clinical Research Of CTGF And TGF-β1in Duchenne Muscular Dystrophy

Objective:The purpose is to analyze the expression of CTGF and TGF-P1in skeletal muscle of DMD patients, further insight into the pathogenesis; Investigate the relationship between the diagnosed age of DMD patients, the degree of pathology, the degree of clinical significance and CTGF and TGF-β1to clarify the clinic value.Methods:Select patients clinically suspected DMD or other myopathy treated by open skeletal muscle biopsy. DMD group contains18cases present deficency of dystrophin protein. The control group contains8cases suspected myopathy, but the result of muscle biopsy was normal. By immunohistochemical staining, the Image-proplus6.0image analysis software detects groups of CTGF and TGF-β1expression, use integral optical density(IOD) said, comparation between the two groups, analyze the relationship between diagnosed age, the degree of pathology, the degree of clinical significance with CTGF and TGF-β1.Results:1. Clinical analysis:all of18DMD patients are male, average diagnosis of age is6.88±2.33years old; The main clinical manifestations are myasthenia, for example, walking unsteadily, easy failing, going up staircase difficultly.2. Histochemical staining findings: all DMD patients showed typical muscular dystrophy.3. Immunohistochemical staining results:IOD of CTGF and TGF-β1in among the two groups (the DMD group, normal control group) are different significance (P<0.05). There are not significant differences statistically with diagnosed age (P>0.05), and are significantly different in the degree of pathology and the degree of clinical significance (P<0.05).Conclusions:1. The expression of CTGF and TGF-β1in skeletal muscle of DMD patients is increased.2. With the degree of pathology and the degree of clinical significance severity, the expression of CTGF and TGF-β1gradually increased obviously, suggesting that these two factors involved in the fibrosis of DMD and could be co-determining factors in DMD.